Protocol Ledger

NCT05305040 · Phase II/III · TERMINATED

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Interventional Phase II/III clinical trial protocol NCT05305040 sponsored by AlloVir in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-24 Enrollment: 451 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05305040
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)451 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05305040
Protocol FieldVerified Registry Value
NCT IdentifierNCT05305040
Consolidated Lead SponsorAlloVir
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment451 participants (ACTUAL)
Registered Start Date2022-03-24
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI